Wolverine Fund invests in $21 mln funding round for NeuMoDx Molecular
The University of Michigan's Ross School of Business' venture fund, the Wolverine Venture Fund, has participated in a $21 million Series B funding round in NeuMoDx Molecular Inc., a diagnosis company developing a platform for high throughput, low cost molecular testing. The Wolverine fund is managed by students at The Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies. The funding round was led by Pfizer Ventures and included investments from Baird Capital, Venture Investors and existing investor Arboretum Ventures.
2 April 2014•4 mins read
